Premium
Dextromethorphan: polymorphic serum pattern of the O‐demethylated and didemethylated metabolites in man.
Author(s) -
Mortimer O.,
Lindstrom B.,
Laurell H.,
Bergman U.,
Rane A.
Publication year - 1989
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1989.tb05354.x
Subject(s) - dextromethorphan , debrisoquine , dextrorphan , metabolite , urine , pharmacology , pharmacokinetics , placebo , active metabolite , medicine , chemistry , cyp2d6 , metabolism , cytochrome p450 , alternative medicine , pathology
1. The interindividual differences in serum concentrations of dextromethorphan (DM) and its metabolites were studied in 29 healthy subjects given 120 mg orally. They were also phenotyped according to the urinary ratio of debrisoquine and 4‐hydroxy‐debrisoquine. 2. Four (14%) subjects were found to be poor metabolizers (PM) with a dextromethorphan/dextrorphan metabolite ratio in plasma of 3.6 or more compared with extensive metabolizers (EM) with a ratio of 0.11 or less. Significant levels of 3‐hydroxymorphinan were measurable in all individuals except two, both of whom were PMs. This subdivision corresponded to the phenotype determined by the metabolic ratio of debrisoquine (r = 0.92). 3. Twelve of the 29 subjects reported adverse drug reactions after dextromethorphan administration compared with none after placebo.